Status:

COMPLETED

Laparoscopic Hepatectomy and Radiofrequency Ablation in the Treatment of Early Hepatocellular Carcinoma

Lead Sponsor:

ChenJian

Conditions:

Hepatocellular Carcinoma

Eligibility:

All Genders

18-70 years

Phase:

NA

Brief Summary

The purpose of this research is to compare short-term and long-term efficacy of laparoscopic hepatectomy and radiofrequency ablation in the Treatment of early hepatocellular carcinoma, and provide the...

Detailed Description

Background:The aim of this study was to compare the efficacy of laparoscopic hepatectomy(LH) with radiofrequency ablation (RFA) in the treatment of early hepatocellular carcinoma (HCC). Methods:A tot...

Eligibility Criteria

Inclusion

  • Any gender,18 to 70 years old;
  • Preoperative diagnosis of primary liver clear;
  • No active hepatitis and decompensated cirrhosis;
  • Maximum diameter ≤3cm single nodules or three nodules in diameter and no more than 3cm,did not infringe the portal vein,hepatic vein and inferior vena cava invasion,lymph node or extrahepatic turn;
  • No tumor rupture or bleeding;
  • Child-Pugh class A or B grade,ICG-R15 \<14%;
  • No coagulation disorders,platelet count \> 50 × 109 / L and prolonged prothrombin time \< 5 seconds;
  • Not be including related surgery,radiofrequency ablation (RFA),TACE treatment,no certainty anticancer chemotherapy treatment;supreme absolute contraindications abdominal surgery;
  • Patients generally available,heart and lung function can tolerate surgery, abdominal surgery supreme absolute contraindications;
  • Voluntarily participate in the study,informed consent.

Exclusion

  • Age \< 18 years or \> 70,pregnant and lactating women;
  • Primary liver cancer diagnosis is not clear
  • Liver function assessment:Child-PughC level,liver function reserve situation :ICGR-15\> 14%
  • Tumor rupture has occurred,or has the line before surgery,radiofrequency ablation (RFA),TACE or chemotherapy cancer treatment;
  • Tips liver imaging with multiple ( \> 3 ) lesion,or tumor diameter\> 3 cm, clear portal vein,hepatic vein,inferior vena cava tumor thrombus trunk;
  • Preoperative liver metastasis;
  • Preoperative evaluation of cardiopulmonary dysfunction patients who can not tolerate surgery;
  • Intraoperative exploration has occurred disseminated tumor and / or lymph node metastasis;
  • Exploratory surgery found that non-hepatic primary tumors,such as colorectal metastases,hilar cell carcinoma;
  • Severe upper abdominal adhesions;
  • Postoperative pathological examination of the bile duct cell or mixed cell carcinoma and pathologically confirmed positive margin;
  • Foreign,Hong Kong,Macao,Taiwan and other regions,estimated postoperative difficult to track,followed up.

Key Trial Info

Start Date :

September 1 2014

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 1 2021

Estimated Enrollment :

150 Patients enrolled

Trial Details

Trial ID

NCT02243384

Start Date

September 1 2014

End Date

October 1 2021

Last Update

June 2 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

JianChen

Chongqing, Chongqing Municipality, China, 400038